A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

By D. Morgan, D. Diamond, P. Gottschall, K. Ugen, C. Dickey, John Hardy, K. Duff, P. Jantzen, G. Dicarlo, D. Wilcock and 5 more. Nature, 2000

650 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/27a31207fbce08d645e7f1739d65a2a0085a9d69

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Selkoe
2. Shaomin Li
3. M. Jin
4. K. Ono
5. M. Westerman
6. John Hardy
7. G. Shankar
8. L. Kotilinek

Citations in the corpus

• The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease (2002, methodology): “…the onset of memory loss to the appearance of A insol depend on the validity of assigning the onset of decline in spatial reference memory to 6 months, a time point that differs from all other published results (Hsiao et al., 1996; Holcomb et al., 1999; King et al., 1999; Morgan et al., 2000).”
• The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal (2009, background): “…this immediately ameliorated the subtle behavioral alterations in transgenic APP animals was interpreted as indicating that this prediction had been fulfilled in animals (Janus et al. 2000; Morgan et al. 2000; Dodart et al. 2002), but as indicated above, perhaps this interpretation was premature.”
• Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models (2014, background): “…14: (Yassine et al., 2013), 15: (Westerman et al., 2002), 16: (Corcoran et al., 2002), 17: (Oules et al., 2012), 18: (Lassalle et al., 2008), 19: (Morgan et al., 2000), 20: (Sturchler-Pierrat et al., 1997), 21: (Van Dam et al., 2003), 22: (Huang et al., 2006), 23: (Heneka et al., 2006), 24:…”
• Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro (2004, background): “Vaccination (Schenk et al., 1999; Janus et al., 2000; Morgan et al., 2000) and secretase inhibitors (Skovronsky et al.”
• Alzheimer's Disease: Targeting the Cholinergic System (2016, background): “Immunization of transgenic mice with a synthetic Aβ peptide (ative immunization) has shown satisfactory results in minimizing cognitive dysfunction [267], including rescuing short-term memory deficit [268] and reducing amyloid deposition in the brain of both young and old mice [269].”
• Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors (2011, background): “Importantly, A immunotherapy can protect against the neuropathology and cognitive deficits observed in APP transgenic mice (Janus et al., 2000; Morgan et al., 2000) and also prevent the LTP inhibition induced by A oligomers (Klyubin et al.”
• Microglia as a source and target of cytokines (2002, background): “Considering processes even serving in the clearance of already aggregated A and the removal of existing deposits, vaccination experiments in an APP-transgenic mouse model resulted in both prevention as well as clearance and improved CNS function (Schenk et al., 1999; Morgan et al., 2000).”